A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Recruiting now · Phase 1

Conditions studied: Multiple Myeloma (MM)

In brief

The main purpose of the study is to understand the safety and tolerability of cemsidomide when given along with elranatamab in subjects with relapsed or refractory multiple myeloma. The first part of the study will evaluate different dose levels of cemsidomide in combination with elranatamab in a limited number of subjects. Approximately 3 different dose levels of cemsidomide in combination with elranatamab may be explored. Once a dose level is determined safe, additional subjects may be enrolled through expansion of the dose level. This expansion will provide further exploration of the safety and evaluation of preliminary antimyeloma activity. Cemsidomide will be taken orally each cycle for 14 days on/14 days off (1 cycle=28 days). Elranatamab will be administered by subcutaneous injection twice a month. Dexamethasone will be administered weekly until a confirmed response but no longer than 4 cycles.

Key facts

Study ID

NCT07280013

Run by

C4 Therapeutics, Inc.

People needed

60

Starts

2026-02-06

Expected to finish

2029-06-01

Last updated by the study team

2026-07-14

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of multiple myeloma as defined by IMWG criteria
• Measurable disease based on IMWG criteria
• Received 2-4 prior lines of therapy (escalation part) and 1-3 prior lines of therapy (expansion part) for multiple myeloma, consisting of at least 1 immunomodulatory drug (i.e., IKZF 1/3 degrader)
• ECOG performance status 0-2

You may not qualify if…

• Active plasma cell leukemia, Smoldering multiple myeloma, POEMS Syndrome, systemic light chain amyloidosis, MDS
• Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
• Participants with any active, uncontrolled bacterial, fungal, or viral infection
• Prior treatment with a BCMA-directed TCE or BCMA-directed CAR-T therapy
• Administration with an investigational product within 30 days preceding the first dose of study intervention
• Inability or difficulty swallowing tablets, malabsorption syndrome, or any disease or medical condition significantly affecting gastrointestinal function

Where it is running

• University of Maryland Greenbaum Comprehensive Cancer Center — Baltimore, Maryland, United States (enrolling)
• START Midwest — Grand Rapids, Michigan, United States (enrolling)
• Memorial Sloan Kettering Cancer Center — New York, New York, United States (enrolling)
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States (enrolling)
• University of Miami — Miami, Florida, United States
• Loyola University Medical Center — Maywood, Illinois, United States
• Indiana University — Indianapolis, Indiana, United States
• Norton Cancer Institute St. Matthews — Louisville, Kentucky, United States
• University of Nebraska — Omaha, Nebraska, United States
• Dartmouth-Hitchcock Medical Center — Lebanon, New Hampshire, United States
• Perlmutter Cancer Center at NYU Langone Hospital — Brooklyn, New York, United States
• Duke Cancer Center — Durham, North Carolina, United States
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States
• Baylor University Medical Center — Dallas, Texas, United States
• Houston Methodist Hospital — Houston, Texas, United States
• Banner MD Anderson Cancer Center — Gilbert, Arizona, United States
• Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah, United States
• UC Davis Comprehensive Cancer Center — Sacramento, California, United States
• UCLA Health, Jonsson Comprehensive Cancer Center — Santa Monica, California, United States
• University of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.